+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Lung Cancer Diagnostics Market Size, Share, Global Forecast 2022-2027, Industry Trends, Impact of COVID-19, Opportunity Company Analysis

  • PDF Icon

    Report

  • 135 Pages
  • November 2021
  • Region: Global
  • Renub Research
  • ID: 5504336
Globally, lung cancer occurs when cells divide in the lungs uncontrollably - further causing tumours to grow, which reduces a person's ability to breathe and spread to other parts of the body. Moreover, lung cancer is amongst the most common cancer and the leading cause of cancer-related death worldwide. Smoking is a significant risk factor, though everyone who develops lung cancer does not have a smoking history. Lung cancer can be fatal. Nevertheless, effective diagnoses and treatments are improving the outlook. According to the this research, Lung Cancer Diagnostics Market is projected to reach US$ 3.6 Billion by 2027.



Types of Lung Cancer Prevailing in the Global Market


The two chief types of lung cancer are small-cell lung cancer and non-small cell lung cancer, depending on their appearance under a microscope. Small cell lung cancer (SCLC) spreads promptly in the body, making detecting this cancer at an early stage. However, only about 10% of the fatalities are small cell lung cancers. There are two dominant subtypes of SCLC, combined small-cell lung carcinoma and small-cell lung carcinoma.

Non-small cell lung cancer (NSCLC) is the unique form of cancer and accounts for 85% of lung cancer cases. Moreover, multiple subtypes of NSCLC include large cell carcinoma, adenocarcinoma, squamous cell carcinoma, and other less frequent types of NSCLCs. As per our analysis, non-small cell lung cancer dominates small cell lung cancer around the world.

Worldwide Lung Cancer Diagnosis Industry will grow with a CAGR of 7.75% during 2021 to 2027


Imaging tests activity is the primary screening technique used for lung cancer diagnosis. Imaging tests assist as the initial screening mechanism for lung cancer diagnostics and are helpful throughout the treatment period. Wherein the high usage rates of various imaging techniques, including X-rays, Magnetic resonance imaging (MRI) scans (which use magnetic fields), Ultrasound (which uses sound waves) and Nuclear tests (which use radioactive substances to trace) are involved. Moreover, if cancer has spread, imaging tests can also reveal changes to bones and other organs. Consequently, helping to track treatment progress and capture the highest market share in the Lung Cancer Diagnostics Market.

Global Lung Cancer Diagnostics Market Size was US$ 2.3 Billion in 2021


Globally, lung cancer patients visit the hospitals & clinics for cancer-related and unrelated reasons more often than patients visiting diagnostics centres and research institutes with their lung cancer-related issues. Further, this results in the dominance of the hospitals & clinics dealing in admissions and lung cancer diagnosis. Moreover, as the patients frequently require emergency medical care due to acute unbearable symptoms and life-threatening conditions, hospitals & clinics serve as immediate help. As per our analysis, hospitals dominate the end-user segment in the Lung Cancer Diagnostics Market.

North America is the largest Lung Cancer Diagnosis Market and expected to remain its dominance in forecast period


North America, Europe and the Asia Pacific are analyzed at the regional forefront in the report. As per our analysis, North America is identified as the largest regional market with the highest market share throughout the forecasted period. The largest market share is attributed to the increased market invasion rates of technologically advanced products, the increasing patient awareness, and the growing smoking prevalence level in the region.

In addition, the presence of a favourable reimbursement framework (wildly succeeding the implementation of the Affordable Care Act) and sophisticated healthcare infrastructure is expected to promote the usage rates of diagnostics devices in North America. Initiatives, such as smoking suspension programs administered by the American Lung Association (ALA) and campaigns to enhance knowledge of the symptoms of lung cancer, are anticipated to boost the regional market growth further.

Besides, Asia Pacific is projected to capture a lucrative growth in market share during the projection period. Major factors accountable for the fastest growth exhibited in the Asia Pacific include the rising penetration of advanced lung cancer diagnostic tools in the region and the increasing awareness about the disease symptoms.

Competitive Landscape Existing in the Market


The lung cancer diagnostics market is highly fragmented, with a large number of local and international players. Key players adopt different growth policies to magnify their market presence, including partnerships, agreements, collaborations, new product launches, geographical augmentations, mergers and acquisitions. Some of the chief players in the industry are Illumina, Inc., Abbott Laboratories, Thermo Fisher Scientific, Inc, QIAGEN N.V. and Roche Holding AG.

Recent Launches in Lung Cancer Diagnosis Field


In September 2020, Illumina acquired GRAIL, a healthcare company concentrated in multi-cancer early apprehension, for about USD 8 billion. The acquisition will also combine the company's latest product, Galleri multi-cancer screening test.

In June 2020, Roche announced to launch 'uPath PD-L1 (SP263), a CE-IVD marked automated digital pathology algorithm for detecting non-small cell lung cancer. It is an image analyzer that supports diagnosing non-small cell lung cancer.

COVID-19 Pandemic affect on the Lung Cancer Diagnostics


At the origin of the COVID-19 pandemic, elective medical procedures, including lung cancer screening, were principally put on hold to prioritize urgent necessities and reduce the risk of the spread of COVID-19 in healthcare settings at the beginning of 2021. One effect of this has been a significant drop in the lung cancer diagnostics industry compared to 2020 as the pandemic started spreading at a rapid pace in H1 of 2021. Most healthcare facilities were offering elective procedures again, including lung cancer diagnostic declining the all over market in 2021.

This report “Lung Cancer Diagnostic Market, Global Forecast By Diagnosis Test Type (Imaging Test, Biopsy, Sputum Cytology, Molecular Test and Others), Lung Cancer Type (Small-cell Lung Cancer Diagnostics and Non-Small-cell Lung Cancer Diagnostics), End-User (Hospitals & Clinics, Diagnostic Centers, Research Institute and Others), Region (North America, Europe, Asia Pacific and Rest of World), Companies (Illumina, Inc., Abbott Laboratories, Thermo Fisher Scientific, Inc, QIAGEN N.V. and Roche Holding AG)” provides a detailed analysis of Lung Cancer Diagnostic Industry.

Diagnosis Test Type – Global Lung Cancer Diagnostics Market has been covered from 5 viewpoints:


1. Imaging Test
2. Biopsy
3. Sputum Cytology
4. Molecular Test
5. Others

Lung Cancer Type – Global Lung Cancer Diagnostics Market has been covered from 2 viewpoints:


1. Small-cell Lung Cancer Diagnostics
2. Non-Small-cell Lung Cancer Diagnostics

Non-Small-cell Lung Cancer Diagnostics has been segmented into 4 viewpoints:


1. Adenocarcinoma
2. Squamous Cell Carcinoma
3. Large cell carcinoma
4. Others and not otherwise specified

End-User – Global Lung Cancer Diagnostics Market has been covered from 4 viewpoints:


1. Hospitals & Clinics
2. Diagnostic Centers
3. Research Institute
4. Others

Regions – Global Lung Cancer Diagnostics Market has been covered from 4 viewpoints:


1. North America
2. Europe
3. Asia Pacific
4. ROW

Company Insights:

  • Overviews
  • Recent Developments
  • Revenues

Company Analysis:


1. llumina, Inc.
2. Abbott Laboratories
3. Thermo Fisher Scientific, Inc
4. QIAGEN N.V.
5. Roche Holding AG.
Frequently Asked Questions about the Global Lung Cancer Diagnostics Market

What is the estimated value of the Global Lung Cancer Diagnostics Market?

The Global Lung Cancer Diagnostics Market was estimated to be valued at $2.3 Billion in 2021.

What is the growth rate of the Global Lung Cancer Diagnostics Market?

The growth rate of the Global Lung Cancer Diagnostics Market is 7.8%, with an estimated value of $3.6 Billion by 2027.

What is the forecasted size of the Global Lung Cancer Diagnostics Market?

The Global Lung Cancer Diagnostics Market is estimated to be worth $3.6 Billion by 2027.

Who are the key companies in the Global Lung Cancer Diagnostics Market?

Key companies in the Global Lung Cancer Diagnostics Market include llumina, Inc., Abbott Laboratories, Thermo Fisher Scientific, Inc and Roche Holding AG..

Table of Contents

1. Introduction2. Research & Methodology3. Executive Summary
4. Market Dynamics
4.1 Growth Drivers
4.2 Challenges
5. Global Lung Cancer Diagnostics Market
6. Market Share Analysis
6.1 Diagnosis Test Type
6.2 Lung cancer Type
6.2.1 Non-Small-cell Lung Cancer Diagnostics Types
6.3 End-User
6.4 Regions
7. Diagnosis Test Type – Global Lung Cancer Diagnostics Market
7.1 Imaging Test
7.2 Biopsy
7.3 Sputum Cytology
7.4 Molecular Test
7.5 Others
8. Lung Cancer Type – Global Lung Cancer Diagnostics Market
8.1 Small-cell Lung Cancer Diagnostics
8.2 Non-Small-cell Lung Cancer Diagnostics
8.2.1 Adenocarcinoma
8.2.2 Squamous Cell Carcinoma
8.2.3 Large cell carcinoma
8.2.4 Others and not otherwise specified
9. End-User – Global Lung Cancer Diagnostics Market
9.1 Hospitals & Clinics
9.2 Diagnostic Centers
9.3 Research Institute
9.4 Others
10. Regions – Global Lung Cancer Diagnostics Market
10.1 North America
10.2 Europe
10.3 Asia Pacific
10.4 ROW
11. Company Analysis
11.1 llumina, Inc..
11.1.1 Overviews
11.1.2 Recent Developments
11.1.3 Revenues
11.2 Abbott Laboratories
11.2.1 Overviews
11.2.2 Recent Developments
11.2.3 Revenues
11.3 Thermo Fisher Scientific, Inc
11.3.1 Overviews
11.3.2 Recent Developments
11.3.3 Revenues
11.4 QIAGEN N.V.
11.4.1 Overviews
11.4.2 Recent Developments
11.4.3 Revenues
11.5 Roche Holding AG.
11.5.1 Overviews
11.5.2 Recent Developments
11.5.3 Revenues
List Of Figures:
Figure-01: Global Lung Cancer Diagnostics Market (Million US$), 2016 – 2021
Figure-02: Forecast for – Global Lung Cancer Diagnostics Market (Million US$), 2022 – 2027
Figure-03: Diagnosis Test Type – Imaging Test Market (Million US$), 2016 – 2021
Figure-04: Diagnosis Test Type – Forecast for Imaging Test Market (Million US$), 2022 – 2027
Figure-05: Diagnosis Test Type – Biopsy Market (Million US$), 2016 – 2021
Figure-06: Diagnosis Test Type – Forecast for Biopsy Market (Million US$), 2022 – 2027
Figure-07: Diagnosis Test Type –Sputum Cytology Market (Million US$), 2016 – 2021
Figure-08: Diagnosis Test Type – Forecast for Sputum Cytology Market (Million US$), 2022 – 2027
Figure-09: Diagnosis Test Type – Molecular Test Market (Million US$), 2016 – 2021
Figure-10: Diagnosis Test Type – Forecast for Molecular Test Market (Million US$), 2022 – 2027
Figure-11: Diagnosis Test Type – Others Market (Million US$), 2016 – 2021
Figure-12: Diagnosis Test Type – Forecast for Others Market (Million US$), 2022 – 2027
Figure-13: Product – Small-cell Lung Cancer Diagnostics Market (Million US$), 2016 – 2021
Figure-14: Product – Forecast for Small-cell Lung Cancer Diagnostics Market (Million US$), 2022 – 2027
Figure-15: Product – Non-Small-cell Lung Cancer Diagnostics Market (Million US$), 2016 – 2021
Figure-16: Product – Forecast for Non-Small-cell Lung Cancer Diagnostics Market (Million US$), 2022 – 2027
Figure-17: Product – Adenocarcinoma Market (Million US$), 2016 – 2021
Figure-18: Product – Forecast for Adenocarcinoma Market (Million US$), 2022 – 2027
Figure-19: Product – Squamous Cell Carcinoma Market (Million US$), 2016 – 2021
Figure-20: Product – Forecast for Squamous Cell Carcinoma Market (Million US$), 2022 – 2027
Figure-21: Product – Large Cell Carcinoma Market (Million US$), 2016 – 2021
Figure-22: Product – Forecast for Large Cell Carcinoma Market (Million US$), 2022 – 2027
Figure-23: Product – Others and not Otherwise Specified Market (Million US$), 2016 – 2021
Figure-24: Product – Forecast for Others and not Otherwise Specified Market (Million US$), 2022 – 2027
Figure-25: End-User – Hospitals & Clinics Market (Million US$), 2016 – 2021
Figure-26: End-User – Forecast for Hospitals & Clinics Market (Million US$), 2022 – 2027
Figure-27: End-User – Diagnostic Centers Market (Million US$), 2016 – 2021
Figure-28: End-User – Forecast for Diagnostic Centers Market (Million US$), 2022 – 2027
Figure-29: End-User – Research Institute Market (Million US$), 2016 – 2021
Figure-30: End-User – Forecast for Research Institute Market (Million US$), 2022 – 2027
Figure-31: End-User – Others Market (Million US$), 2016 – 2021
Figure-32: End-User – Forecast for Others Market (Million US$), 2022 – 2027
Figure-33: North America – Lung Cancer Diagnostics Market (Million US$), 2016 – 2021
Figure-34: North America – Forecast for Lung Cancer Diagnostics Market (Million US$), 2022 – 2027
Figure-35: Europe – Lung Cancer Diagnostics Market (Million US$), 2016 – 2021
Figure-36: Europe – Forecast for Lung Cancer Diagnostics Market (Million US$), 2022 – 2027
Figure-37: Asia Pacific – Lung Cancer Diagnostics Market (Million US$), 2016 – 2021
Figure-38: Asia Pacific – Forecast for Lung Cancer Diagnostics Market (Million US$), 2022 – 2027
Figure-39: Rest of World – Lung Cancer Diagnostics Market (Million US$), 2016 – 2021
Figure-40: Rest of World – Forecast for Lung Cancer Diagnostics Market (Million US$), 2022 – 2027
Figure-41: llumina, Inc. – Global Revenue (Million US$), 2016 – 2021
Figure-42: llumina, Inc. – Forecast for Global Revenue (Million US$), 2022 – 2027
Figure-43: Abbott Laboratories – Global Revenue (Million US$), 2016 – 2021
Figure-44: Abbott Laboratories – Forecast for Global Revenue (Million US$), 2022 – 2027
Figure-45: Thermo Fisher Scientific, Inc – Global Revenue (Million US$), 2016 – 2021
Figure-46: Thermo Fisher Scientific, Inc – Forecast for Global Revenue (Million US$), 2022 – 2027
Figure-47: QIAGEN N.V. – Global Revenue (Million US$), 2016 – 2021
Figure-48: QIAGEN N.V. – Forecast for Global Revenue (Million US$), 2022 – 2027
Figure-49: Roche Holding AG. – Global Revenue (Million US$), 2016 – 2021
Figure-50: Roche Holding AG. – Forecast for Global Revenue (Million US$), 2022 – 2027
List Of Tables:
Table-01: Global – Lung Cancer Diagnostics Market Share by Diagnosis Test Type (Percent), 2016 – 2021
Table-02: Global – Forecast for Lung Cancer Diagnostics Market Share by Diagnosis Test Type (Percent), 2022 – 2027
Table-03: Global –Market Share by Lung Cancer Type (Percent), 2016 – 2021
Table-04: Global – Forecast for Market Share by Lung Cancer Type (Percent), 2022 – 2027
Table-05: Global – Market Share by Non-Small-cell Lung Cancer Diagnostics Types (Percent), 2016 – 2021
Table-06: Global – Forecast for Market Share by Non-Small-cell Lung Cancer Diagnostics Types (Percent), 2022 – 2027
Table-07: Global – Lung Cancer Diagnostics Market Share by End-User (Percent), 2016 – 2021
Table-08: Global – Forecast for Lung Cancer Diagnostics Market Share by End-User (Percent), 2022 – 2027
Table-09: Global – Lung Cancer Diagnostics Market Share by Region (Percent), 2016 – 2021
Table-10: Global – Forecast for Lung Cancer Diagnostics Market Share by Region (Percent), 2022 – 2027

Companies Mentioned

  • llumina, Inc.
  • Abbott Laboratories
  • Thermo Fisher Scientific, Inc
  • QIAGEN N.V.
  • Roche Holding AG.

Methodology

In this report, for analyzing the future trends for the studied market during the forecast period, the publisher has incorporated rigorous statistical and econometric methods, further scrutinized by secondary, primary sources and by in-house experts, supported through their extensive data intelligence repository. The market is studied holistically from both demand and supply-side perspectives. This is carried out to analyze both end-user and producer behavior patterns, in the review period, which affects price, demand and consumption trends. As the study demands to analyze the long-term nature of the market, the identification of factors influencing the market is based on the fundamentality of the study market.

Through secondary and primary researches, which largely include interviews with industry participants, reliable statistics, and regional intelligence, are identified and are transformed to quantitative data through data extraction, and further applied for inferential purposes. The publisher's in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of their recommendations and advice.

Primary Research

The primary purpose of this phase is to extract qualitative information regarding the market from the key industry leaders. The primary research efforts include reaching out to participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions. The publisher also established professional corporate relations with various companies that allow us greater flexibility for reaching out to industry participants and commentators for interviews and discussions, fulfilling the following functions:

  • Validates and improves the data quality and strengthens research proceeds
  • Further develop the analyst team’s market understanding and expertise
  • Supplies authentic information about market size, share, growth, and forecast

The researcher's primary research interview and discussion panels are typically composed of the most experienced industry members. These participants include, however, are not limited to:

  • Chief executives and VPs of leading corporations specific to the industry
  • Product and sales managers or country heads; channel partners and top level distributors; banking, investment, and valuation experts
  • Key opinion leaders (KOLs)

Secondary Research

The publisher refers to a broad array of industry sources for their secondary research, which typically includes, however, is not limited to:

  • Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
  • Patent and regulatory databases for understanding of technical & legal developments
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic new articles, webcasts, and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecasts
 

Loading
LOADING...